AAAlaa Eddin Alhmeidi Alkhatib

Alaa Eddin Alhmeidi Alkhatib

*This is an algorithmically generated author record based on publicly available information.

Alaa Eddin Alhmeidi Alkhatib has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Role of urban discharges in regulating the dynamics of river water quality to antibiotic resistance in subtropical river basins

    by Niteesh Kumar Pandey, Alaa Eddin Alhmeidi Alkhatib, Monika Simon, Rajesh Kumar Vishwakarma, Jagdeesh Kumar, V. Srikanth, Sumit Sen, Himanshu Joshi, Shweta Yadav, Javier Mateo-Sagasta, et al.

  • Top Cited Papers

    Beyond structure and activity: targeting class A carbapenemases with monocyclic and bicyclic boronic acids to counter antimicrobial resistance

    by Kunal Dhankhar, Mousumi Hazra, Adwaita S. R. Nair, Alaa Eddin Alhmeidi Alkhatib, Narayan C. Mishra, Saugata Hazra

    Bicyclic boronic acids inhibit SME-1 carbapenemase via a unique π–π stacking with His105 and covalent interaction with Ser70.


  • Microbial PHB/PCL Nanofibrous Scaffolds for Controlled Drug Delivery and Enhanced Wound Healing: Comprehensive In Vitro and In Vivo Evaluation

    by Komal Singh, Gireesh Kumar Shroti, Siddhartha D. Pramanik, Alaa Eddin Alhmeidi Alkhatib, Samrat Chauhan, Partha Roy, Debarati Chattopadhyay, Narayan Chandra Mishra, Saugata Hazra

    Wound management remains a significant global challenge due to delayed epithelialization, microbial infections, and resistance to traditional antibiotics. Particularly, in the era of antibiotic resistance, the combination of drugs has gained prominence due to their broad-spectrum antibacterial action, which enhances the efficacy of topical formulations for wound healing. The study explores the fabrication and evaluation of an electrospun nanofibrous scaffold composed of microbial poly-3-hydroxybutyrate (PHB) and polycaprolactone (PCL) loaded with a dual drug combination of cefixime (CFX) and azithromycin (AZM) for controlled drug delivery (CDD) in wound healing. PHB was produced from Bacillus cereus using sugar hydrolysate as a low-carbon source. Furthermore, the PHB polymer is blended with PCL to enhance flexibility, spinnability, and drug release performance. The nanofibrous scaffolds were fabricated by varying the PHB/PCL (3:1 and 1:1) ratio via electrospinning. FTIR and 1H NMR analyses confirmed successful drug incorporation in PHB3/PCL1/CFX/AZM and PHB1/PCL1/CFX/AZM nanofibrous scaffolds. In vitro drug release studies revealed a sustained dual drug release profile with the Korsmeyer-Peppas best-fitting model, suggesting anomalous (non-Fickian) transport governed by diffusion and swelling or erosion phenomena. The drug-loaded scaffold demonstrated significant antibacterial activity against Escherichia coli, Acinetobacter baumannii, Staphylococcus aureus, and Enterococcus faecalis, achieving complete inhibition over 24 h. In vitro results reveal that the dual drug-loaded PHB/PCL scaffolds show good biocompatibility and enhanced cell proliferation and migration via a scratch assay. Additionally, in vivo studies displayed improved wound closure, reepithelialization, neovascularization, and collagen remodeling in treated wounds. These results suggest that a dual drug-loaded PHB/PCL nanofibrous scaffold, designed for CDD, offers a promising platform for wound healing management.


  • Structural Insights into the Role of the Stereochemistry of the Cyclopropyl Ring in the Inhibitory Activity of Xeruborbactam against SME-1 Class A Carbapenemase

    by Kunal Dhankhar, Adwaita S R Nair, Mousumi Hazra, Alaa Eddin Alhmeidi Alkhatib, Subhecchha Baidya, Narayan C Mishra, Saugata Hazra

    Xeruborbactam is a boronic acid-based transition-state analogue that has exhibited great potential as a clinically relevant inhibitor of carbapenemase enzymes, including class A carbapenemases. In this work, we have investigated the mechanism of inhibition of xeruborbactam against SME-1 carbapenemase using kinetic, structural, and thermodynamic approaches. With a Ki(app) of 4 nM, xeruborbactam shows more potent inhibitory activity than any other beta-lactamase inhibitor available until now. Structural data from crystal complexes revealed that xeruborbactam covalently engages Ser70 at the active site and forms stabilizing interactions; in particular, the cyclopropyl group forms hydrophobic interactions with His105, further stabilizing the adduct, which correlates with a high rate of borylation and minimal deborylation. We investigated xeruborbactam with its 2R,3S-cyclopropyl isomer to grasp the influence of the stereochemistry of the cyclopropyl ring. Although both inhibitors bind covalently to Ser70 in SME-1, the 2R,3S-isomer adopts a different conformation of the cyclopropyl ring, which makes the C3 carbon much farther from His105, Asn132, and Lys73, thereby decreasing the binding affinity and Ki(app) of the isomer. Furthermore, the fluorine-12 atom takes different conformations in the two structures, changing the terrain of interaction with the protein. Consistent with its lowered inhibition efficiency, the 2R,3S-isomer shows a lower borylation rate and weaker enzyme-inhibitor binding. In the molecular dynamics, xeruborbactam stabilized SME-1 more than its isomer, which is consistent with our experimental findings. These results together show the strong inhibitory profile of xeruborbactam and highlight the importance of stereochemistry in the design of next-generation β-lactamase inhibitors and diagnostics for AMR.